

Date: 30 January 2026

To,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Dear Madam/Sir,

Sub: Analysts/Investors call

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of 3Q- FY26 Earnings Conference Call, which is to be held on Friday, 06 February 2026 at 16.00 hrs.

A copy of this intimation is also being made available at: <https://www.vbshilpa.com/investor-presentation.php>

We request you to take the above information on record.

Thanking you.

Yours faithfully,
For Shilpa Medicare Limited

Ritu Tiwary
Company Secretary & Compliance officer



Shilpa Medicare Limited 3QFY26 Earnings Conference Call

Shilpa Medicare Limited (BSE:530549; NSE: SHILPAMED) will announce its results for the third quarter ended December 31, 2025, on **Friday, February 6, 2026**

The management of the Company will host its earnings call on **Friday, February 6, 2026**
at 16:00 hrs

Details of Earnings Conference Call

Day/Date	Friday, February 6, 2026
Time	16:00 hrs
Universal Access	+91 22 6280 1130 +91 22 7115 8031

The number listed above is universally accessible from all networks and all countries

International Toll-Free Numbers

USA	18667462133
UK	08081011573
Singapore	8001012045
Hong Kong	800964448
DiamondPass™ Link	Click here to join with DiamondPass™ (No Wait Time)

Participants are requested to dial-in 10 minutes before the scheduled time

About Shilpa Medicare Limited (SML)

Shilpa Medicare Limited (SML) is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio. The company also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.

For more information, visit www.vbshilpa.com

For further details, please get in touch with

Shilpa Medicare Ltd
Monish Shah
E: monish.shah@vbshilpa.com